{"entity":{"id":"nct03780049","kind":"trial","name":"HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B","aka":[],"tldr":"A phase 3 trial of H101 oncolytic adenovirus in Hepatocellular carcinoma, run by Sun Yat-sen University, with a status the registry has not verified recently.","summary":"HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B is a phase 3 interventional study registered as NCT03780049 by Sun Yat-sen University, with 304 participants planned, started 2018-10-01 and due to reach its primary completion in 2023-10-01. Interventions recorded: HAIC of FOLFOX, H101, Placebos. Conditions recorded: Hepatocellular Carcinoma.\n\nLinked to the drug H101 oncolytic adenovirus because the registry names it among its interventions and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03780049","url":"https://clinicaltrials.gov/study/NCT03780049"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["h101-oncolytic-adenovirus"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03780049","phase":"3","setting":"Hepatic Artery Infusion Chemotherapy Plus Recombinant Human Type-5 Adenovirus vs Hepatic Artery Infusion Chemotherapy Alone for Unresectable Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer A-B Stage","sponsor":"Sun Yat-sen University","enrolled":304,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03780049/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"h101-oncolytic-adenovirus","kind":"drug","name":"H101 oncolytic adenovirus","route":"/drugs/h101-oncolytic-adenovirus/"}]}}